Department of Pediatrics, Alberta Research Centre for Health Evidence, University of Alberta, Edmonton, Alberta, Canada.
Clinical Pharmacology Unit, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal.
J Clin Epidemiol. 2020 Sep;125:9-15. doi: 10.1016/j.jclinepi.2020.04.026. Epub 2020 May 19.
The objective of the study was to evaluate the inter-rater and intercenter reliability, usability, and utility of A MeaSurement Tool to Assess systematic Reviews (AMSTAR), AMSTAR 2, and Risk Of Bias In Systematic reviews (ROBIS).
This is a prospective evaluation using 30 systematic reviews of randomized trials, undertaken at three international centers.
Reviewers completed AMSTAR, AMSTAR 2, and ROBIS in median (interquartile range) 15.7 (11.3), 19.7 (12.1), and 28.7 (17.4) minutes and reached consensus in 2.6 (3.2), 4.6 (5.3), and 10.9 (10.8) minutes, respectively. Across all centers, inter-rater reliability was substantial to almost perfect for 8/11 AMSTAR, 9/16 AMSTAR 2, and 12/24 ROBIS items. Intercenter reliability was substantial to almost perfect for 6/11 AMSTAR, 12/16 AMSTAR 2, and 7/24 ROBIS items. Intercenter reliability for confidence in the results of the review or overall risk of bias was moderate (Gwet's first-order agreement coefficient (AC1) 0.58, 95% confidence intervals [CI]: 0.30 to 0.85) to substantial (AC1 0.74, 95% CI: 0.30 to 0.85) for AMSTAR 2 and poor (AC1 -0.21, 95% CI: -0.55 to 0.13) to moderate (AC1 0.56, 95% CI: 0.30 to 0.83) for ROBIS. It is not clear whether using the appraisals of any tool as an inclusion criterion would alter an overview's findings.
Improved guidance may be needed to facilitate the consistent interpretation and application of the newer tools (especially ROBIS).
本研究旨在评估评价系统评价的测量工具(AMSTAR)、AMSTAR 2 和系统评价偏倚风险(ROBIS)的评分者间信度、中心间信度、可用性和实用性。
这是一项在三个国际中心进行的前瞻性评估,使用了 30 项随机试验的系统评价。
审稿人分别在中位数(四分位距)15.7(11.3)、19.7(12.1)和 28.7(17.4)分钟内完成了 AMSTAR、AMSTAR 2 和 ROBIS 的评估,并分别在 2.6(3.2)、4.6(5.3)和 10.9(10.8)分钟内达成共识。在所有中心,8/11 的 AMSTAR、9/16 的 AMSTAR 2 和 12/24 的 ROBIS 项目的评分者间信度为中等至高。6/11 的 AMSTAR、12/16 的 AMSTAR 2 和 7/24 的 ROBIS 项目的中心间信度为中等至高。对综述结果或总体偏倚风险的信心的中心间信度为中等(Gwet 一阶一致性系数(AC1)0.58,95%置信区间[CI]:0.30 至 0.85)到高(AC1 0.74,95% CI:0.30 至 0.85)对于 AMSTAR 2 和差(AC1 -0.21,95% CI:-0.55 至 0.13)到中等(AC1 0.56,95% CI:0.30 至 0.83)对于 ROBIS。尚不清楚使用任何工具的评估作为纳入标准是否会改变综述的结果。
可能需要改进指导,以促进对新工具(特别是 ROBIS)的一致解释和应用。